# Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years

> **NCT00783653** · PHASE1,PHASE2 · COMPLETED · sponsor: **Universitätsklinikum Hamburg-Eppendorf** · enrollment: 22 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT00783653
- **Lead sponsor:** Universitätsklinikum Hamburg-Eppendorf
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2013-07
- **Final completion:** —
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2020-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00783653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00783653, "Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years". Retrieved via MORVS 2026-10-16 from https://api.morvs.ai/clinical/NCT00783653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*